Alas some people's loss are other peoples gain. I went a bit too...

Alas some people's loss are other peoples gain. I went a bit too early, but I am buying in here - I feel sorry for long-term shareholders taking the hit. I suspect the 4Q results, when they are reported, will be decent, speaking to some contacts on the ground in Singapore, with a little insight. Doesnt help when a clowny CEO says at the lowest quarterly cash report in 9 quarters that:

"Company CEO, Khoon Seng Goh, has identified a gradual trend towards pre-pandemic business activity and is confident that the Company will resume its sales growth trajectory by Q1 CY22."

Perhaps he has an excellent crystal ball model that identifies forwards trends. Communication is universally bad in Aussie bio-techs, without fail. I cannot tell you how many bio-tech companies I am on with excellent products, that management gaff up trials in, guided timelines, regulatory applications and most of all, simple clear communication to the very capital markets which sustain their nice half million salaries, stock and share options....whilst they consistently fail to grow cash flows as promised.